These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21059303)

  • 41. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
    Malone DC; Tran TT; Poordad FF
    J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?
    Dusheiko G; Danta M
    Nat Clin Pract Gastroenterol Hepatol; 2005 Mar; 2(3):130-1. PubMed ID: 16265150
    [No Abstract]   [Full Text] [Related]  

  • 43. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
    Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
    von Wagner M; Hofmann WP; Teuber G; Berg T; Goeser T; Spengler U; Hinrichsen H; Weidenbach H; Gerken G; Manns M; Buggisch P; Herrmann E; Zeuzem S
    Hepatology; 2008 Nov; 48(5):1404-11. PubMed ID: 18846541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin: some issues.
    Wu KT; Yang JF; Chuang WL; Yu ML
    J Hepatol; 2010 Feb; 52(2):305; author reply 305-6. PubMed ID: 20006403
    [No Abstract]   [Full Text] [Related]  

  • 46. Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report.
    Taffaro M; Pyrsopoulos N; Cedron H; Cacayorin E; Weppler D; Moon J; Nishida S; Levi D; Kato T; Selvaggi G; Tzakis A; Schiff E
    Dig Dis Sci; 2007 Dec; 52(12):3435-7. PubMed ID: 17431776
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
    Arora S; O'Brien C; Zeuzem S; Shiffman ML; Diago M; Tran A; Pockros PJ; Reindollar RW; Gane E; Patel K; Wintfeld N; Green J
    J Gastroenterol Hepatol; 2006 Feb; 21(2):406-12. PubMed ID: 16509866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ribavirin with interferon for hepatitis C in dialysis patients: efficacious and safe in the right patients in good hands.
    Mutimer D
    Gut; 2015 Feb; 64(2):190-1. PubMed ID: 24861270
    [No Abstract]   [Full Text] [Related]  

  • 49. Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients.
    Chung WJ
    Clin Mol Hepatol; 2012 Sep; 18(3):268-71. PubMed ID: 23091806
    [No Abstract]   [Full Text] [Related]  

  • 50. Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis.
    Mederacke I; Witte T; Wedemeyer H; Meyer-Olson D
    Ann Rheum Dis; 2011 Jul; 70(7):1343-4. PubMed ID: 21131645
    [No Abstract]   [Full Text] [Related]  

  • 51. [Acquired hemophilia A in a patient with chronic hepatitis C virus infection receiving treatment with peginterferon α-2a].
    Martínez Pascual C; Antón Ródenas G; Ortiz Sánchez ML; Pons Miñano JA
    Med Clin (Barc); 2013 Sep; 141(5):228-9. PubMed ID: 23473306
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment of patients with dual hepatitis B and C: a step in the right direction.
    Aghemo A; Colombo M
    Gut; 2014 Mar; 63(3):380-1. PubMed ID: 23921890
    [No Abstract]   [Full Text] [Related]  

  • 53. "Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.
    Schulze Zur Wiesch J; Pudelski N; Hoepner L; Supplieth M; Buggisch P; Lohse AW; Lüth S
    Hepatology; 2011 Apr; 53(4):1405-6; author reply 1407. PubMed ID: 21480360
    [No Abstract]   [Full Text] [Related]  

  • 54. Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral.
    Mishra A; Younossi Z
    Aliment Pharmacol Ther; 2013 Sep; 38(5):557-8. PubMed ID: 23937466
    [No Abstract]   [Full Text] [Related]  

  • 55. Chronic hepatitis C successfully treated with telaprevir, pegylated interferon and ribavirin in severe aplastic anemia.
    Balkan II; Bozcan S; Yemisen M; Kutlubay Z; Ozaras R
    Ann Hepatol; 2014; 13(6):843-4. PubMed ID: 25332274
    [No Abstract]   [Full Text] [Related]  

  • 56. Mild hepatitis C: treat or monitor.
    Main J; Thomas H
    J Viral Hepat; 2006 May; 13(5):289. PubMed ID: 16637857
    [No Abstract]   [Full Text] [Related]  

  • 57. Basic answers to complicated questions for the course of chronic hepatitis C treatment.
    Örmeci N; Erdem H
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):371-82. PubMed ID: 22646258
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of hepatitis C infection: towards eradication of chronic virus].
    Ahola T; Kaukinen P
    Duodecim; 2012; 128(18):1911-7. PubMed ID: 23088003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comment on a systematic review of randomized trials of peginterferon alpha-2a versus peginterferon alpha-2b in chronic hepatitis C.
    Singal AK; Jampana SC; Anand BS
    Hepatology; 2011 Jun; 53(6):2151. PubMed ID: 21538429
    [No Abstract]   [Full Text] [Related]  

  • 60. Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral--authors' reply.
    Ferenci P; Rutter K
    Aliment Pharmacol Ther; 2013 Sep; 38(5):558. PubMed ID: 23937467
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.